Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
203.82
+4.31 (2.16%)
At close: Jan 22, 2026, 4:00 PM EST
203.89
+0.07 (0.03%)
After-hours: Jan 22, 2026, 5:53 PM EST
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $243.5, which forecasts a 19.47% increase in the stock price over the next year. The lowest target is $220 and the highest is $275.
Price Target: $243.5 (+19.47%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 10, 2025.
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $234 → $235 | Buy | Maintains | $234 → $235 | +15.30% | Dec 10, 2025 |
| Stifel | Stifel | Strong Buy Maintains $220 → $230 | Strong Buy | Maintains | $220 → $230 | +12.84% | Dec 10, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $270 | Strong Buy | Initiates | $270 | +32.47% | Dec 9, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $185 → $234 | Buy | Maintains | $185 → $234 | +14.81% | Nov 10, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $250 → $275 | Buy | Maintains | $250 → $275 | +34.92% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
246.87M
from 167.13M
Increased by 47.71%
Revenue Next Year
270.99M
from 246.87M
Increased by 9.77%
EPS This Year
7.73
from -0.22
EPS Next Year
8.46
from 7.73
Increased by 9.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 276.8M | 291.9M | ||||
| Avg | 246.9M | 271.0M | ||||
| Low | 226.5M | 252.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 65.6% | 18.2% | ||||
| Avg | 47.7% | 9.8% | ||||
| Low | 35.5% | 2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 8.06 | 9.31 | ||||
| Avg | 7.73 | 8.46 | ||||
| Low | 7.33 | 7.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 20.5% | ||||
| Avg | - | 9.4% | ||||
| Low | - | -5.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.